Pharmaceuticals

Multiple Sclerosis Drugs Market Forecast 2026–2035 Reflecting Growth Opportunities Across Industries

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Multiple Sclerosis Drugs Market From 2026 To 2030?

The multiple sclerosis drugs market has experienced significant expansion recently. It is set to increase from $33.46 billion in 2025 to $37.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.6%. This historical growth can be linked to factors such as the limited availability of ms therapies, the rising prevalence of multiple sclerosis, enhanced awareness among patients and physicians, the dependence on interferon-based therapies, and the widening reach of hospital and retail pharmacy networks.

The multiple sclerosis drugs market size is anticipated to experience significant expansion over the next few years. It is projected to climb to $61.43 billion by 2030, achieving a compound annual growth rate (CAGR) of 13.0%. This projected growth is driven by the advancement of new monoclonal antibodies, the increased availability of oral disease-modifying therapies, the incorporation of personalized medicine into MS treatment, growing investments in research and development for emerging treatments, and the increasing uptake of digital health monitoring and telemedicine platforms. Prominent trends expected in the forecast period include the heightened acceptance of disease-modifying therapies for multiple sclerosis, an expansion of personalized and targeted MS treatment strategies, the broadening of distribution channels through hospitals and retail pharmacies, a rising preference for oral and parenteral administration routes, and the introduction of novel immunomodulators, immunosuppressants, and monoclonal antibodies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2817&type=smp

What Major Drivers Are Influencing Demand In The Multiple Sclerosis Drugs Market?

The expansion of the multiple sclerosis drugs market is supported by both governmental and non-governmental organizations. These entities fund various programs and schemes to enhance the quality of life for individuals affected by multiple sclerosis (MS). For example, the government of Alberta, partnering with the Department of Economic Development, Trade, and Tourism in Canada, invested $1 million into the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). This investment was made to advance research and innovations for improved understanding and treatment of MS disease. CanProCo is an effort aimed at consolidating the work of nearly 50 MS researchers from various disciplines across Canada. The initiative received further funding from the Canada Brain Research, Biogen Canada, the MS Society of Canada, and Hoffmann-La Roche Limited (Roche Canada), collectively raising a total of $10 million. Sufficient financial backing from government and non-government organizations significantly boosts the growth of the multiple sclerosis drugs market.

Which Segments Are Included In The Analysis Of The Multiple Sclerosis Drugs Market?

The multiple sclerosis drugs market covered in this report is segmented –

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes

2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores

3) By Route Of Administration: Oral Drugs, Parenteral Drugs

Subsegments:

1) By Immunomodulators: Glatiramer Acetate, Fingolimod, Teriflunomide, Dimethyl Fumarate

2) By Immunosuppressants: Natalizumab, Alemtuzumab, Ocrelizumab

3) By Interferons: Interferon Beta-1a, Interferon Beta-1b

4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators, Monoclonal Antibodies, Other Emerging Therapies

Which Trends Are Impacting The Growth Of The Multiple Sclerosis Drugs Market?

Companies operating in the multiple sclerosis drugs market are concentrating on the development of innovative solutions aimed at improving the effectiveness of treatments, enhancing the quality of life for patients, and meeting the varied needs of individuals afflicted with multiple sclerosis. These innovative solutions involve new and imaginative methods, products, or technologies designed to efficiently address specific difficulties or problems. An example of this is Genentech, a US-based biotechnology company, which declared in September 2024 that the U.S. Food and Drug Administration (FDA) had given its approval to Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo represents the inaugural and sole subcutaneous injection, administered by healthcare professionals, which is given just twice a year and takes about 10 minutes, thereby offering people with MS more choices for their treatment.

Which Key Industry Participants Are Active In The Multiple Sclerosis Drugs Market?

Major companies operating in the multiple sclerosis drugs market are Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

Read the full multiple sclerosis drugs market report here:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Multiple Sclerosis Drugs Market?

North America was the largest region in the global multiple sclerosis drug market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Multiple Sclerosis Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2817&type=smp

Browse Through More Reports Similar to the Global Multiple Sclerosis Drugs Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Macular Degeneration Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795